Lycia Therapeutics Inc(LYCA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
LYCA
New Lycia Therapeutics Inc
$30.00
+12.00 ▲ +66.67%
Oct 23 at 7:38 PM ET (Korea 10/24 08:38)$26.50
-3.50 ▼ -11.67%
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | - | Shs Outstand | 52.1M | Perf Week | - |
| Market Cap | 1.56B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | - | Perf Month | - |
| Enterprise Value | - | PEG | - | EPS next Q | - | Inst Own | - | Short Float | - | Perf Quarter | - |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | - | Perf Half Y | - |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | - | Perf YTD | - |
| Book/sh | - | P/C | - | EPS past 3/5Y | - | ROE | - | 52W High | - | Perf Year | - |
| Cash/sh | - | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | - | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | - | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 14.3 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | - | EPS Q/Q | - | Profit Margin | - | RSI (14) | - | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | - | Sales Q/Q | - | SMA20 | 0% ($30) | Beta | - | Target Price | - |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | 0% ($30) | Rel Volume | - | Prev Close | $18 |
| Employees | 65 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | 0% ($30) | Avg Volume(3M) | - | Price | $30 |
| IPO | 2026/10/23 | Option/Short | No/No | Trades | 19923 | Volume | 2,287,448 | Change | 66.67% |
Company
Lycia Therapeutics IncLYCA | NASD | Biotechnology 🧬 세포 밖으로 분비된 단백질을 리소좀으로 끌어들여 분해하는 플랫폼을 보유한 임상 단계 바이오테크입니다. 스탠퍼드대 연구진의 기반 기술에서 출발해 자가면역·염증·알레르기 질환을 겨냥하며, 미국 캘리포니아 사우스샌프란시스코에 본사를 두고 나스닥에 상장되어 있습니다.
Quote
Over the past 1 year, roughly in the middle
52W Range-
Volume 2,287,448
Has it trended upward long-term? B
Long-term returns are roughly flat
Tap to view numbers
How about dividends?
No dividend
There is no profit to distribute yet.
Who owns it? B
Ownership is about average
Shareholder Composition Guide
Tap to view numbers
Peer comparison Biotechnology
It ranks #122 of 595 in the industry
Based on market cap of $2B.
TRAX#119 First Tracks Biotherapeutics Inc $2B PER - 
ABSI#120 Absci Corp $2B PER - 
NTLA#121 Intellia Therapeutics Inc $2B PER - LYCA#122 Lycia Therapeutics Inc $2B PER - 
QURE#123 uniQure NV $2B PER - Reads on this stock 1 posts
FAQ
Briefs · earnings · signals, first Telegram · KakaoTalk channels
